Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study.

ABSTRACT:

Background

Although infliximab (IFX) has been available since 2005, there are very little data on the long-term drug survival of infliximab in real-life.

Objective

Our aim was to identify and describe psoriasis patients treated with IFX for longer than 6 years.

Methods

Psoriasis patients treated with IFX for longer than 6 years were retrospectively included. Demographic and clinical data were collected in May 2018.

Results

Between January 2005 and December 2012, 43 patients were maintained on IFX for 6 years or longer. IFX was introduced as a 4.5 line of systemic therapy. The mean duration of IFX treatment was 8.5 years (6-12). In May 2018, 30 patients (70%) were still maintained on IFX at 4-6 mg/kg every 8-10 weeks with an efficiency of about 100%. IFX was sto

SUBMITTER: Carlet C 

PROVIDER: S-EPMC7085387 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature